

Doug Coyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8852678/publications.pdf>

Version: 2024-02-01

135
papers

4,253
citations

136740

32
h-index

128067

60
g-index

139
all docs

139
docs citations

139
times ranked

6181
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Lancet, The</i> , 2015, 386, 258-265.	6.3	487
2	Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. <i>The Cochrane Library</i> , 2008, , CD001155.	1.5	260
3	Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. <i>The Cochrane Library</i> , 2008, , CD003376.	1.5	237
4	Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. <i>Headache</i> , 2015, 55, 221-235.	1.8	197
5	A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. <i>Systematic Reviews</i> , 2014, 3, 110.	2.5	172
6	Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. <i>The Cochrane Library</i> , 2008, , CD004523.	1.5	169
7	Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. <i>Value in Health</i> , 2013, 16, 498-506.	0.1	127
8	Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1122.	3.8	126
9	Global Estimate of Lung Cancer Mortality Attributable to Residential Radon. <i>Environmental Health Perspectives</i> , 2018, 126, 057009.	2.8	101
10	Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. <i>Systematic Reviews</i> , 2015, 4, 147.	2.5	99
11	Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. <i>BMJ Open</i> , 2014, 4, e004301-e004301.	0.8	93
12	Parents' Needs Following Identification of Childhood Hearing Loss. <i>American Journal of Audiology</i> , 2008, 17, 38-49.	0.5	88
13	Effects of aerobic exercise, resistance exercise or both, on patient-reported health status and well-being in type 2 diabetes mellitus: a randomised trial. <i>Diabetologia</i> , 2010, 53, 632-640.	2.9	84
14	A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. <i>Journal of Cancer Survivorship</i> , 2015, 9, 683-691.	1.5	80
15	Cannabis-based products for pediatric epilepsy: A systematic review. <i>Epilepsia</i> , 2019, 60, 6-19.	2.6	79
16	Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. <i>BMJ: British Medical Journal</i> , 2018, 362, k3478.	2.4	69
17	The Influence of Experiential Knowledge on Prenatal Screening and Testing Decisions. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 115-124.	1.7	64
18	Opportunity Cost of Funding Drugs for Rare Diseases. <i>Medical Decision Making</i> , 2014, 34, 1016-1029.	1.2	53

#	ARTICLE	IF	CITATIONS
19	Auditory and language outcomes in children with unilateral hearing loss. <i>Hearing Research</i> , 2019, 372, 42-51.	0.9	51
20	Parentsâ€™ perspectives on the impact of the early diagnosis of childhood hearing loss. <i>International Journal of Audiology</i> , 2007, 46, 97-106.	0.9	49
21	Children With Mild Bilateral and Unilateral Hearing Loss: Parentsâ€™ Reflections on Experiences and Outcomes: Table 1.. <i>Journal of Deaf Studies and Deaf Education</i> , 2016, 21, 34-43.	0.7	49
22	Statistical Analysis in Pharmacoeconomic Studies. <i>Pharmacoeconomics</i> , 1996, 9, 506-516.	1.7	48
23	Sepsis-Associated Mortality, Resource Use, and Healthcare Costs: A Propensity-Matched Cohort Study*. <i>Critical Care Medicine</i> , 2021, 49, 215-227.	0.4	45
24	An Evaluation Framework for Funding Drugs for Rare Diseases. <i>Value in Health</i> , 2012, 15, 982-986.	0.1	40
25	Cost Effectiveness of Epoetin-?? to Augment Preoperative Autologous Blood Donation in Elective Cardiac Surgery. <i>Pharmacoeconomics</i> , 2000, 18, 161-171.	1.7	38
26	Estimating the expected value of partial perfect information: a review of methods. <i>European Journal of Health Economics</i> , 2008, 9, 251-259.	1.4	38
27	Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 168.	1.2	38
28	The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 12.	1.2	38
29	Cost Effectiveness of Nasal Calcitonin in Postmenopausal Women. <i>Pharmacoeconomics</i> , 2001, 19, 565-575.	1.7	37
30	Hand assisted laparoscopic surgery versus conventional laparoscopy for colorectal surgery. <i>The Cochrane Library</i> , 2010, , CD006585.	1.5	37
31	A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e108749.	1.1	37
32	Cost Effectiveness of a Survivorship Care Plan for Breast Cancer Survivors. <i>Journal of Oncology Practice</i> , 2014, 10, e86-e92.	2.5	36
33	Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1463-1473.	0.8	32
34	EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. <i>BMJ Open</i> , 2014, 4, e006945.	0.8	29
35	Cost Effectiveness of Infant Vaccination for Rotavirus in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2012, 23, 71-77.	0.7	28
36	Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations. <i>Liver International</i> , 2017, 37, 851-861.	1.9	28

#	ARTICLE	IF	CITATIONS
37	ANALYZING DIFFERENCES IN THE COSTS OF TREATMENT ACROSS CENTERS WITHIN ECONOMIC EVALUATIONS. <i>International Journal of Technology Assessment in Health Care</i> , 2001, 17, 155-163.	0.2	27
38	Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia: The Folic Acid Clinical Trial Study. <i>Journal of Pregnancy</i> , 2013, 2013, 1-9.	1.1	27
39	Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 660-668.	1.3	27
40	Child and family experiences with inborn errors of metabolism: a qualitative interview study with representatives of patient groups. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 139-147.	1.7	26
41	Costs associated with infant bronchiolitis in the Baffin region of Nunavut. <i>International Journal of Circumpolar Health</i> , 2005, 64, 38-45.	0.5	25
42	Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. <i>Clinical Oncology</i> , 1997, 9, 313-321.	0.6	24
43	Cannabis-based products for pediatric epilepsy: An updated systematic review. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 75, 18-22.	0.9	24
44	COST-EFFECTIVENESS OF EXERCISE PROGRAMS IN TYPE 2 DIABETES. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 228-234.	0.2	23
45	The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada. <i>PharmacoEconomics - Open</i> , 2020, 4, 27-36.	0.9	22
46	Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds. <i>Blood</i> , 2016, 128, 1032-1032.	0.6	22
47	Cost Analysis of Universal Screening vs. Risk Factor-Based Screening for Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA). <i>PLoS ONE</i> , 2016, 11, e0159667.	1.1	22
48	Toward a Functional Definition of a "Rare Disease" for Regulatory Authorities and Funding Agencies. <i>Value in Health</i> , 2014, 17, 757-761.	0.1	21
49	A review of economic evaluation in osteoporosis. <i>Arthritis and Rheumatism</i> , 1999, 12, 425-434.	6.7	20
50	Estimates of effectiveness and reach for "return on investment" modelling of smoking cessation interventions using data from England. <i>Addiction</i> , 2018, 113, 19-31.	1.7	20
51	Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation. <i>Addiction</i> , 2018, 113, 7-18.	1.7	20
52	Implanted spinal neuromodulation interventions for chronic pain in adults. <i>The Cochrane Library</i> , 2022, 2022, CD013756.	1.5	20
53	The psychometric properties of patient preferences in osteoporosis. <i>Journal of Rheumatology</i> , 2001, 28, 132-7.	1.0	20
54	Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD. <i>Addiction</i> , 2018, 113, 65-75.	1.7	19

#	ARTICLE	IF	CITATIONS
55	Cost-Effectiveness of Hair Apposition Technique Compared With Standard Suturing in Scalp Lacerations. <i>Annals of Emergency Medicine</i> , 2005, 46, 237-242.	0.3	18
56	Application of a Policy Framework for the Public Funding of Drugs for Rare Diseases. <i>Journal of General Internal Medicine</i> , 2014, 29, 774-779.	1.3	18
57	Effectiveness of Outpatient Versus Operating Room Hysteroscopy for the Diagnosis and Treatment of Uterine Conditions: A Systematic Review and Meta-Analysis. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 930-941.	0.3	17
58	Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009994.	1.4	17
59	Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. <i>Value in Health</i> , 2017, 20, 586-592.	0.1	16
60	Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis. <i>Pharmacoeconomics</i> , 2018, 36, 1253-1261.	1.7	16
61	Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 104.	1.2	16
62	Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Phenylketonuria. <i>Pediatrics</i> , 2021, 148, .	1.0	16
63	Is it costâ€Eeffective to provide internetâ€Ebased interventions to complement the current provision of smoking cessation services in the Netherlands? An analysis based on the EQUIPTMOD. <i>Addiction</i> , 2018, 113, 87-95.	1.7	15
64	Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 12.	1.2	15
65	Cannabis for pediatric epilepsy: protocol for a living systematic review. <i>Systematic Reviews</i> , 2018, 7, 95.	2.5	14
66	Value of information analysis for a new technology: Computer-assisted total knee replacement. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 337-342.	0.2	13
67	What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review. <i>Value in Health</i> , 2015, 18, 915-924.	0.1	12
68	Neurologistsâ€™ perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: A qualitative interview study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 78, 118-126.	0.9	12
69	Reducing Periconceptional Methylmercury Exposure: Costâ€EUtility Analysis for a Proposed Screening Program for Women Planning a Pregnancy in Ontario, Canada. <i>Environmental Health Perspectives</i> , 2015, 123, 1337-1344.	2.8	11
70	Parent Report of Amplification Use in Children with Mild Bilateral or Unilateral Hearing Loss. <i>Journal of the American Academy of Audiology</i> , 2019, 30, 093-102.	0.4	11
71	Barriers in accessing medical cannabis for children with drug-resistant epilepsy in Canada: A qualitative study. <i>Epilepsy and Behavior</i> , 2020, 111, 107120.	0.9	11
72	Internet-Based Implementation of Non-Pharmacological Interventions of the "People Getting a Grip on Arthritis" Educational Program: An International Online Knowledge Translation Randomized Controlled Trial Design Protocol. <i>JMIR Research Protocols</i> , 2015, 4, e19.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations. <i>Pharmacoeconomics</i> , 2019, 37, 1261-1276.	1.7	10
74	Cost-Effectiveness of Pharmacological Treatments for Osteoporosis Consistent with the Revised Economic Evaluation Guidelines for Canada. <i>MDM Policy and Practice</i> , 2019, 4, 238146831881884.	0.5	10
75	Comparison of Alternative Sources of Data on Health Service Encounters. <i>Journal of Health Services Research and Policy</i> , 1999, 4, 210-214.	0.8	9
76	The economic evaluation of pharmacotherapies for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 301-307.	1.1	9
77	What Guidance Are Researchers Given on How to Present Network Meta-Analyses to End-Users such as Policymakers and Clinicians? A Systematic Review. <i>PLoS ONE</i> , 2014, 9, e113277.	1.1	9
78	Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys. <i>Trials</i> , 2017, 18, 603.	0.7	9
79	Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 70.	1.2	9
80	The return of investment of hospital-based surgical quality improvement programs in reducing surgical site infection at a Canadian tertiary-care hospital. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 125-132.	1.0	9
81	Global evidence of gender inequity in academic health research: a living scoping review protocol. <i>JBI Evidence Synthesis</i> , 2020, 18, 2181-2193.	0.6	9
82	Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1083-1090.	0.5	9
83	Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 26.	1.2	9
84	Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. <i>Cmaj</i> , 2021, 193, E1551-E1560.	0.9	9
85	The assessment of the economic return from controlled clinical trials. <i>European Journal of Health Economics</i> , 2003, 4, 6-11.	1.4	8
86	Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders. <i>ClinicoEconomics and Outcomes Research</i> , 2016, Volume 8, 427-433.	0.7	8
87	A cost effectiveness analysis of interventions to reduce residential radon exposure in Canada. <i>Journal of Environmental Management</i> , 2019, 247, 449-461.	3.8	8
88	Value of mesenchymal stem cell therapy for patients with septic shock: an early health economic evaluation. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 525-532.	0.2	8
89	Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis. <i>Pharmacoeconomics</i> , 2020, 38, 971-980.	1.7	8
90	Nicotine preloading for smoking cessation: the Preloading RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-84.	1.3	8

#	ARTICLE	IF	CITATIONS
91	Assessment of cost-effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD. <i>Addiction</i> , 2018, 113, 96-105.	1.7	7
92	Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. <i>Systematic Reviews</i> , 2019, 8, 75.	2.5	7
93	Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts. <i>Pharmacoeconomics - Open</i> , 2020, 4, 297-305.	0.9	7
94	Cost-effectiveness of a gestational age metabolic algorithm for preterm and small-for-gestational-age classification. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2021, 3, 100279.	1.3	7
95	Cost-effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD. <i>Addiction</i> , 2018, 113, 52-64.	1.7	6
96	Health Care for Mitochondrial Disorders in Canada: A Survey of Physicians. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 717-726.	0.3	6
97	A technique for approximating transition rates from published survival analyses. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 12.	0.6	6
98	The Impact of Risk on Preference Values: Implications for Evaluations of Postmenopausal Osteoporosis Therapy. <i>Value in Health</i> , 2001, 4, 385-391.	0.1	5
99	Determining utility values related to malaria and malaria chemoprophylaxis. <i>Malaria Journal</i> , 2010, 9, 92.	0.8	5
100	A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. <i>Supportive Care in Cancer</i> , 2017, 25, 2505-2513.	1.0	5
101	A utility of model input uncertainty analysis in transferring tobacco control-related economic evidence to countries with scarce resources: results from the EQUIPT study. <i>Addiction</i> , 2018, 113, 42-51.	1.7	5
102	Service Preferences of Parents of Children With Mild Bilateral or Unilateral Hearing Loss: A Conjoint Analysis Study. <i>Ear and Hearing</i> , 2019, 40, 671-679.	1.0	5
103	Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: A systematic review and network meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3515.	1.7	5
104	Spinal cord stimulation for chronic pain. <i>Lancet Neurology</i> , The, 2022, 21, 405.	4.9	5
105	Utility gains from reductions in the modifiable burden of lung cancer attributable to residential radon in Canada. <i>Canadian Journal of Public Health</i> , 2018, 109, 598-609.	1.1	4
106	Mitral Valve Clip for Treatment of Mitral Regurgitation: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , 2015, 15, 1-104.	3.0	4
107	Cost-effectiveness research in osteoporosis. <i>Drug Development Research</i> , 2000, 49, 135-140.	1.4	3
108	Reimbursement-Based Economics "What Is It and How Can We Use It to Inform Drug Policy Reform?". <i>Headache</i> , 2015, 55, 236-247.	1.8	3

#	ARTICLE	IF	CITATIONS
109	A General Population Utility Valuation Study for Metastatic Epidural Spinal Cord Compression Health States. <i>Spine</i> , 2019, 44, 943-950.	1.0	3
110	Virtual follow-up and care for patients with cardiac electronic implantable devices: protocol for a systematic review. <i>Systematic Reviews</i> , 2020, 9, 153.	2.5	3
111	When piloting health services interventions, what predicts real world behaviours? A systematic concept mapping review. <i>BMC Medical Research Methodology</i> , 2020, 20, 76.	1.4	3
112	Bendamustine and Rituximab Versus Conventional Chemoimmunotherapy As a Frontline Treatment for Patients with Indolent B-Cell Lymphoma: A Cost-Effectiveness Analysis. <i>Blood</i> , 2016, 128, 1186-1186.	0.6	3
113	A cost-utility analysis of the impact of electronic nicotine delivery systems on health care costs and outcomes in Canada. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2022, 42, 29-36.	0.8	3
114	Issues of consensus and debate for economic evaluation in rheumatology. <i>Journal of Rheumatology</i> , 2001, 28, 642-7.	1.0	3
115	Patient decisional needs when considering treatment intensification for type 2 diabetes: A qualitative study in China. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108471.	1.1	2
116	An assessment of uncertainty using two different modelling techniques to estimate the cost effectiveness of mitigating radon in existing housing in Canada. <i>Science of the Total Environment</i> , 2020, 724, 138092.	3.9	2
117	A Retrospective Cohort Study Investigating the Impact of Maternal Pre-Pregnancy Body Mass Index on Pediatric Health Service Utilization. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 1267-1273.	0.3	2
118	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. <i>BMJ Open</i> , 2021, 11, e046707.	0.8	2
119	Application of Operations Research to Funding Decisions for Treatments with Rare Disease. <i>Profiles in Operations Research</i> , 2013, , 281-294.	0.3	2
120	A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. <i>Journal of Clinical Oncology</i> , 2004, 22, 665-665.	0.8	2
121	Pertussis vaccination in pregnancy in Canada: a cost-utility analysis. <i>CMAJ Open</i> , 2020, 8, E651-E658.	1.1	2
122	Program Evaluation of Hospital-Based Antenatal Home Care for High-Risk Women. <i>Healthcare Quarterly</i> , 2003, 6, 67-73.	0.7	1
123	Back to Bayesian: A strategy to enhance prognostication of metastatic spine disease. <i>International Journal of Clinical Practice</i> , 2019, 73, e13322.	0.8	1
124	Outpatient uterine assessment and treatment unit in patients with abnormal uterine bleeding: an economic modelling study. <i>CMAJ Open</i> , 2020, 8, E810-E818.	1.1	1
125	Who would benefit from average value-based pricing?. <i>Health Economics (United Kingdom)</i> , 2020, 29, 936-937.	0.8	1
126	Family Experiences with Care for Children with Inherited Metabolic Diseases in Canada: A Cross-Sectional Survey. <i>Patient</i> , 2022, 15, 171-185.	1.1	1

#	ARTICLE	IF	CITATIONS
127	Regional cost effectiveness analyses for increasing radon protection strategies in housing in Canada. Journal of Environmental Radioactivity, 2021, 240, 106752.	0.9	1
128	RESOURCE ALLOCATION FOR THE TREATMENT OF RARE DISEASES. Journal of Epidemiology and Community Health, 2013, 67, e2.12-e2.	2.0	0
129	DEVELOPING AND TESTING A TOOL FOR ASSESSING PHARMACOECONOMIC EVALUATIONS. Journal of Epidemiology and Community Health, 2013, 67, e2.8-e2.	2.0	0
130	THE EPIDEMIOLOGY AND HEALTH SYSTEM IMPACT OF MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY AMONG AFFECTED CHILDREN AND THOSE WITH FALSE POSITIVE NEWBORN SCREENING RESULTS IN ONTARIO, CANADA. Journal of Epidemiology and Community Health, 2013, 67, e2.3-e2.	2.0	0
131	Designing economic evaluations to facilitate optimal decisions: the need to avoid bias. ClinicoEconomics and Outcomes Research, 2016, 8, 73.	0.7	0
132	Increasing the methodological quality and relevance of cost effectiveness analysis. Thrombosis Research, 2017, 150, 121-122.	0.8	0
133	P253Short-term versus indefinite anticoagulant therapy for secondary prevention of unprovoked venous thromboembolism: a decision analysis. European Heart Journal, 2018, 39, .	1.0	0
134	The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities. PharmacoEconomics - Open, 2019, 3, 197-204.	0.9	0
135	The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases. Pharmacoeconomics, 2021, 39, 479-480.	1.7	0